Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,446 INR
Change Today +13.00 / 0.91%
Volume 5.0M
WPL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

wockhardt ltd (WPL) Snapshot

Open
1,331
Previous Close
1,433
Day High
1,470
Day Low
1,330
52 Week High
04/8/15 - 2,000
52 Week Low
07/10/14 - 543.10
Market Cap
159.2B
Average Volume 10 Days
2.3M
EPS TTM
36.81
Shares Outstanding
110.1M
EX-Date
11/13/14
P/E TM
39.3x
Dividend
20.00
Dividend Yield
1.38%
Current Stock Chart for WOCKHARDT LTD (WPL)

Related News

No related news articles were found.

wockhardt ltd (WPL) Related Businessweek News

No Related Businessweek News Found

wockhardt ltd (WPL) Details

Wockhardt Limited, a pharmaceutical and biotechnology company, together with its subsidiaries, manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. It provides pharmaceutical products in various dosage forms, such as sterile injectables and lyophilised products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; and value-added generics. Its biopharmaceutical products include Glargine that is recombinant long-acting insulin; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing and packaging services for sterile injectables, lyophilisation, solid dose, liquids/ointments/creams, sachets and powders, and specialized products; API manufacturing services; and contract research services. Its research activities comprise pharmaceutical formulations, biopharmaceutical bulk and formulations, novel drug delivery systems, new drug discovery programs, and process engineering for APIs. The company develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. Wockhardt Limited offers its products in India, the United States, Europe, and other countries. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Khorakiwala Holdings and Investments Private Limited.

Founded in 1999

wockhardt ltd (WPL) Top Compensated Officers

Managing Director, Executive Director, Member...
Total Annual Compensation: 13.3M
Founder, Executive Chairman, Group Chief Exec...
Total Annual Compensation: 4.8M
Executive Director, Member of Share Allotment...
Total Annual Compensation: 13.3M
Compensation as of Fiscal Year 2014.

wockhardt ltd (WPL) Key Developments

Wockhardt Ltd. Recommends Dividend on Non-Convertible Cumulative Redeemable Preference Shares; Appoints Narendra Singh as Company Secretary and Compliance Officer

Wockhardt Ltd. at its Board meeting held on May 28, 2015, has recommended dividend of INR 0.0005 per preference share of INR 5 each absorbing a sum of INR 298,557 on 475,659,941 Non-Convertible Cumulative Redeemable Preference shares of INR 5 each and 121,454,927 Optionally Convertible Cumulative Redeemable Preference Shares of INR 5 each. The dividend, if declared at the annual general meeting, will be paid within 30 days from the date of annual general meeting.' The company announced that Mr. Narendra Singh has been appointed as a Company Secretary and Compliance Officer of the Company with effect from May 28, 2015.

Wockhardt Limited Appoints Baldev Raj Arora as Additional Non-Executive and Independent Director

Wockhardt Limited announced that Mr. Baldev Raj Arora, an international business executive, has joined board as additional non-executive and independent director with effect from May 28, 2015. He has worked in leadership role with large MNCs for 44 years and has proven track record of building high performance customer oriented teams, giving outstanding results on sustained basis.

Wockhardt Ltd. Announces Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

Wockhardt Ltd. announced audited consolidated and standalone earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 10,791.4 million compared to INR 10,386.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,015.6 million compared to INR 878.8 million a year ago. Profit from ordinary activities before tax was INR 601.4 million compared to INR 829 million a year ago. Net profit from ordinary activities after tax was INR 330.3 million compared to INR 757 million a year ago. Net profit after taxes, minority interest and share of profit of associates was INR 340.8 million compared to INR 744.5 million a year ago. Diluted EPS before and after extraordinary items was INR 3.06 compared to INR 6.70 a year ago. EBITDA grew by 11% at INR 1,360 million. For the year, on consolidated basis, the company reported net sales/income from operations of INR 44,002.4 million compared to INR 48,303.6 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 6,817 million compared to INR 8,399.1 million a year ago. Profit from ordinary activities before tax was INR 5,753.4 million compared to INR 8,906.7 million a year ago. Net profit from ordinary activities after tax was INR 4,126.9 million compared to INR 8,427.9 million a year ago. Net profit after taxes, minority interest and share of profit of associates was INR 4,049.1 million compared to INR 8,407.1 million a year ago. Diluted EPS before and after extraordinary items was INR 36.39 compared to INR 75.71 a year ago. Capital expenditure was INR 4,310 million. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 4,907.8 million compared to INR 4,204.1 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 298.9 million compared to INR 334.3 million a year ago. Loss from ordinary activities before tax was INR 282 million compared to profit from ordinary activities before tax of INR 320.9 million a year ago. Net loss for the period was INR 140.6 million compared to net profit for the period of INR 223.3 million a year ago. Diluted LPS before and after extraordinary items was INR 1.28 compared to diluted EPS before and after extraordinary items of INR 2.01 a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 18,865.5 million compared to INR 18,052.7 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 784.2 million compared to INR 303.1 million a year ago. Profit from ordinary activities before tax was INR 3,504.3 million compared to INR 2,147.6 million a year ago. Net profit for the period was INR 3,318.2 million compared to INR 1,986.1 million a year ago. Diluted EPS before and after extraordinary items was INR 29.82 compared to INR 17.88 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WPL:IN 1,446.00 INR +13.00

WPL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,882 INR +16.05
Cipla Ltd/India 650.45 INR +6.45
Endo International PLC $84.56 USD +1.62
Ipca Laboratories Ltd 654.70 INR +12.65
Torrent Pharmaceuticals Ltd 1,205 INR -34.10
View Industry Companies
 

Industry Analysis

WPL

Industry Average

Valuation WPL Industry Range
Price/Earnings 35.2x
Price/Sales 3.5x
Price/Book 4.6x
Price/Cash Flow 26.3x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WOCKHARDT LTD, please visit www.wockhardt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.